The most frequently reported fusion partners in NSCLC include kinesin family member 5B–RET (KIF5B–RET), which is the most prevalent RET fusion in de novo RET-rearranged NSCLC, accounting for approximately 70%–80% of RET fusion-positive cases in the treatment-naïve setting; coiled-coil domain containing 6–RET (CCDC6–RET), which accounts for 10%–20% of RET fusions and is more commonly observed in acquired resistance contexts following targeted therapy; and nuclear receptor coactivator 4–RET (NCOA4–RET), which is a less frequent fusion partner, representing approximately 5%–10% of cases. This evidence concerns the gene RET and non-small cell lung carcinoma.